Association of Fibrinolytic Parameters With Early Atherosclerosis
- 15 January 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 91 (2) , 284-290
- https://doi.org/10.1161/01.cir.91.2.284
Abstract
Background Thrombosis, provoked by a rupture of an atherosclerotic plaque, plays a crucial role in precipitating a coronary heart disease event. Its role at the early stage of atherosclerosis has, however, been unclear, but it has been hypothesized that thrombosis or defective fibrinolysis contributes to the progression of atherosclerotic lesions. Methods and Results We studied the association of plasminogen activator inhibitor antigen (PAI-1), tissue-type plasminogen activator antigen (TPA), and D-dimer with early atherosclerosis in a cross-sectional case-control study involving 457 pairs chosen from the biracial cohort of the Atherosclerosis Risk in Communities (ARIC) Study. As examined by B-mode ultrasound, patients (cases) had intima-media thickness of carotid arteries above the 90th percentile and control subjects had thickness below the 75th percentile of the ARIC cohort. Persons with a history of heart disease, stroke, or claudication were excluded from the case-control selection. PAI-1, TPA, and D-dimer were higher in patients than in control subjects ( P ≤.001, Wilcoxon signed rank statistic). In conditional logistic regression analyses, the odds ratios of carotid atherosclerosis were, for PAI-1, for example, 1.22, 1.54, and 1.60 in the second, third, and fourth quartiles compared with the first quartile ( P <.0001, test of linear trend, adjusting for age, systolic blood pressure, total cholesterol, acetylsalicylic acid use, and time of blood draw). Corresponding tests for D-dimer and TPA also showed an increasing trend ( P <.0001). Conclusions The findings support the hypothesis that thrombosis and fibrinolysis play a role at the early stage of the atherosclerotic process.Keywords
This publication has 32 references indexed in Scilit:
- Prospective study of endogenous tissue plasminogen activator and risk of strokeThe Lancet, 1994
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart diseaseThe Lancet, 1993
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- Hypercoagulability: Introduction and PerspectiveSeminars in Thrombosis and Hemostasis, 1990
- Assessment of hypercoagulable states by measurement of activation fragments and peptidesBlood Reviews, 1990
- Fibrin and Fibrinogen-Related Antigens in Patients with Stable and Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1987
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- ROLE OF ENDOTHELIUM IN SEQUESTRATION OF LIPOPROTEIN AND FIBRINOGEN IN AORTIC LESIONS, THROMBI, AND GRAFT PSEUDO-INTIMASThe Lancet, 1979